New Delhi: Prime Minister Narendra Modi today undertook a three city tour to conduct extensive review of the vaccine development and manufacturing process. He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune.
The scientists expressed joy that the Prime Minister met them face to face in order to boost their morale and help accelerate their efforts at this critical juncture in the vaccine development journey. Prime Minister expressed pride in the fact that India’s indigenous vaccine development has progressed at such a rapid pace so far. He spoke on how India is following sound principles of science in the entire journey of vaccine development, while also asking for suggestions to make the vaccine distribution process better.
Prime Minister stressed that India considers vaccines as not only vital to good health but also as a global good, and it is India’s duty to assist other countries, including the nations in our neighbourhood, in the collective fight against the virus.
He asked the scientists to express their free and frank opinion on how the country could further improve its regulatory process. The scientists also presented an overview of how they are also developing various new and repurposed drugs to better fight COVID-19.
Upon his visit to Zydus Biotech Park in Ahmedabad, the Prime Minister said, “Visited the Zydus Biotech Park in Ahmedabad to know more about the indigenous DNA based vaccine being developed by Zydus Cadila. I compliment the team behind this effort for their work. Government of India is actively working with them to support them in this journey.”
After undertaking the visit to Bharat Biotech facility in Hyderabad, the Prime Minister said, “At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress.”
After visiting the Serum Institute, the Prime Minister tweeted, “Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility.”